UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages 106-109

  Lynch, Bernadette M ^a   Stern, Edward P ^a   Ong, Voon ^a   Harber, Mark ^b   Burns, Aine ^b   Denton, Christopher P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Acute kidney injury (AKI); Kidney; Renal; Systemic sclerosis

Indexed keywords

CORTICOSTEROID; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CONVALESCENCE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; HUMAN; KIDNEY BIOPSY; KIDNEY DISEASE; MICROSCOPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCLERODERMA; SCLERODERMA RENAL CRISIS; TREATMENT PLANNING; ACUTE KIDNEY INJURY; CLINICAL PATHWAY; COMPLICATION; CONSENSUS; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; HYPERTENSION; MORTALITY; NEPHROLOGY; PREDICTIVE VALUE; RENAL REPLACEMENT THERAPY; RHEUMATOLOGY; SCLERODERMA, SYSTEMIC; STANDARDS; TREATMENT OUTCOME; UNITED KINGDOM;

ACUTE KIDNEY INJURY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ANTICONVULSANTS; ANTIHYPERTENSIVE AGENTS; CONSENSUS; CRITICAL PATHWAYS; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; NEPHROLOGY; PREDICTIVE VALUE OF TESTS; RENAL REPLACEMENT THERAPY; RHEUMATOLOGY; RISK FACTORS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84994460512     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. BARNES J, MAYES MD: Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012; 24: 165-70.
2. PENN H, HOWIE AJ, KINGDON EJ et al.: Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100: 485-94.
3. TEIXEIRA L, MOUTHON L, MAHR A et al.: Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008; 67: 110-6.
4. DENTON CP, LAPADULA G, MOUTHON L, MüLLER-LADNER U: Renal complications and scleroderma renal crisis. Rheumatology 2009; 48 (Suppl. 3): iii32-5.
5. LOGEE KM, LAKSHMINARAYANAN S: Scleroderma renal crisis as an initial presentation of systemic sclerosis: a case report and review of the literature. Clin Exp Rheumatol 2015; 33 (Suppl. 91): S171-4.
6. NIKPOUR M, HISSARIA P, BYRON J et al.: Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011; 13: R211.
7. WALKER JG, AHERN MJ, SMITH MD et al.: Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Intern Med J 2014; 33: 216-20.
8. ZAWADA ET, CLEMENTS PJ, FURST DA, BLOOMER HA, PAULUS HE, MAXWELL MH: Clinical course of patients with scleroderma renal crisis treated with captopril. Nephron 1981; 27: 74-8.
9. STEEN VD, MEDSGER TA: Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4.
10. CASKEY FJ, THACKER EJ, JOHNSTON PA, BARNES JN: Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet 1997; 349: 620.
11. CHEUNG WY, GIBSON IW, RUSH D, JEFFERY J, KARPINSKI M: Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. Am J Kidney Dis 2005; 45: 930-4.
12. PENN H, DENTON CP: Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol 2008; 20: 692-6.
13. HUDSON M, BARON M, TATIBOUET S, FURST DE, KHANNA D: Exposure to ACE inhibitors prior to the onset of scleroderma renal crisisresults from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 2014; 43: 666-72.
14. STEEN VD: Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133: 600.
15. CHIGHIZOLA CB, PREGNOLATO F, MERONI PL, DENTON CP, ONG VH: N-terminal pro Brain Natriuretic Peptide as predictor of outcome in scleroderma renal crisis. Clin Exp Rheumatol 2016; 34 (Suppl.100): S122-28.
16. DENTON CP, SWENY P, ABDULLA A, BLACK CM: Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 1994; 33: 90-2.
17. NUNOKAWA T, AKAZAWA M, YOKOGAWA N et al.: Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report. Am J Ther 2014; 21: e130-3.
18. GIBNEY EM, PARIKH CR, JANI A, FISCHER MJ, COLLIER D, WISEMAN AC: Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity. Am J Transplant 2004; 4: 2027-31.
19. PHAM P-TT, PHAM P-CT, DANOVITCH GM et al.: Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant 2005; 5: 2565-9.